A Study of Effect on Topical Clocortolone ( Purantix ) in Psoriasis and Eczema.
- Author:
E Joong KIM
;
En Sook BANG
;
Myung Sil KIM
- Publication Type:Clinical Trial ; Original Article
- MeSH:
Adrenal Cortex Hormones;
Dermatitis;
Dermatitis, Atopic;
Eczema*;
Erythema;
Pruritus;
Psoriasis*;
Skin;
Skin Diseases
- From:Korean Journal of Dermatology
1977;15(3):309-312
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Clocortolone pivalate (Purantix') is a new dihalogenated corticosteroid for topical use, posessing powerful anti-inflammatory, anti-pruriginous, anti-allergic, anti-exudative and anti-proliferative activity. We are clinical trial to evaluate its efficacy and tolerance when used at a concentration of 0.1% in an oil-in-water base, in several dermatoses normally responsive to topical corticosteroids. In a study of 30 cases, Purantix' was shown to be highly effective in the treatment of various forms of eczema and dermatitis. It was also shown to be highly effective in most cases of atopic dermatitis, and outstanding benefit was obtained in the relief of pruritus in all conditions and highly significant for erythema, weeping, scaling and lichenification. Among these 30 cases, we observed excellent effects in 13 pts(48.3%), good effects in 11 pts (36.6%) and fair effects in 5 pts(16.6%). Namely among these 30 pts, 24 pts(80%) revealed excellent to good therapeutic effects on their skin conditions with Purantix'. No untoward side effect was noted in all subjects treated with Purantix'.
